Fear Extinction and Mechanisms of Change in Obsessive Compulsive Disorder
Obsessive Compulsive Disorder
About this trial
This is an interventional treatment trial for Obsessive Compulsive Disorder focused on measuring OCD, Neuroimaging, Fear Extinction, Behavior Therapy
Eligibility Criteria
Inclusion Criteria:
- Outpatient men and women age 18 to 60, proficient in English, and able to give informed consent
- For OCD patients only: Primary OCD that causes at least moderate distress and/or impairment (Y-BOCS total score > 16)
Exclusion Criteria:
- Current clinically significant suicidality and/or BDI-II suicide item (#9) score >1
- Current or history of neurologic or psychiatric disease (e.g., mental retardation, dementia, brain damage, or other cognitive impairment) that would interfere with ability to engage in BT
- Psychopathology not appropriate for the treatment (such as substance abuse or dependence within the past 3 months; current manic episode; psychosis)
- Previous treatment with ≥4 sessions of BT for OCD
- Currently receiving any other psychotherapy or planning to initiate such treatment during the study
- Use of conventional antipsychotic medications or medications that would lower seizure threshold in high doses or may otherwise affect cerebral metabolism (other than to those required for stabilization of OCD).
- Use of benzodiazepines within 2 weeks prior to study is not allowed. Use of other psychotropic medications (e.g., SSRIs and atypical antipsychotics) will be allowed provided the dose has been stable for > 8 weeks. Planning on initiation or dose change of psychotropic medication during the study.
- Impaired (or uncorrected) vision, medical illness, or medical treatment that would likely interfere with participation.
- History of head injury resulting in prolonged loss of consciousness and/or neurological sequelae; History of seizures; History of stroke; Signs of increased intracranial pressure; Prior neurosurgical procedure
- Metal in the body, metal injury to the eyes; Implanted pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit, or ventriculo-peritoneal shunt
- Pregnancy; breastfeeding or nursing; if the patient cannot rule out the possibility of pregnancy, a pregnancy test (to be ruled out by urine ß-HCG) will be conducted prior to study
- Weight > 250 lbs
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Immediate Behavior Therapy
Waitlist Behavior Therapy
If assigned to the immediate BT condition, patients will be asked to make about 24 visits to our clinics at MGH, including an initial assessment, 12 therapy visits over 12 weeks, and 1 booster session (Week 16). Patients will be asked to come to the clinic for assessments during weeks 4 and 6 and after the treatment (week 12), as well as 1 follow-up visit (week 24). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.
Patients will wait for 12 weeks before starting BT. In this case, they will be asked to make about 21 visits to our clinics, including an initial assessment visit, 12 therapy visits, and 1 booster session. Patients will be asked to come to the clinic for assessments during (weeks 4 and 6) and after the waiting period (week 12). Additionally, patients will participate in 6 MRI scanning sessions at the Charlestown Navy Yard.